Tsumura Shosaikotokakikyosekko : 42 sachets(for two weeks)
|Manufacturer||TSUMURA & CO.|
|Brand||TSUMURA & CO.|
|Shipping Schedule||about 3 weeks after payment|
TSUMURA Shosaikotokakikyosekko Extract Granules (he-reafter TJ-109) is indicated for the relief of the following symptoms accompanied by painful swollen throat:Tonsillitis and peritonsillitis
Light yellow-brown Granules
7.5 g (3sachets for 1day) of TSUMURA Shosaikotokakikyosekko extract granules contains 5.0 g of a dried extract of the following mixed crude drugs.JP Gypsum 10.0g, JP Bupleurum Root 7.0g, JP Pinellia Tuber 5.0g, JP Scutellaria Root 3.0g, JP Platycodon Root 3.0g, JP Jujube 3.0g, JP Ginseng 3.0g, JP Glycyrrhiza 2.0g, JP Ginger 1.0g, (JP: The Japanese Pharmacopoeia)
TSUMURA Shosaikotokakikyosekko Extract Granules (hereafter TJ-109) is indicated for the relief of the following symptoms accompanied by painful swollen throat: Tonsillitis and peritonsillitis
The usual adult dose is 7.5 g/day orally in 2 or 3 divided doses before or between meals.
The dosage may be adjusted according to the patient's age and body weight, and symptoms.
When TJ-109 is used, the patient’s “SHO” (constitution/symptoms) should be taken into account.
The patient’s progress should be carefully monitored, and if no improvement in symptoms/findings is observed,
continuous treatment should be avoided.
Since TJ-109 contains Glycyrrhiza, careful attention should be paid to the serum potassium level, blood
pressure, etc., and if any abnormality is observed, administration should be discontinued.
When TJ-109 is coadministered with other Kampo-preparations (Japanese traditional herbal medicines), etc., attention should be paid to the duplication of the contained crude drugs.
SHO: The term “SHO” refers to a particular pathological status of a patient evaluated by the Kampo diagnosis, and is
patterned according to the patient’s constitution, symptoms, etc. Kampo-preparations (Japanese traditional herbal medicines) should be used after confirmation that it is suitable for the identified “SHO” of the patient.
(1) Clinically significant adverse reactions
1) Pseudoaldosteronism:Pseudoaldosteronism such as hypokalemia, increased blood pressure, retention of sodium/body fluid, edema, increased body weight, etc. may occur. The patient should be carefully monitored (measurement of serum potassium level, etc.) and if any abnormality is observed, administration should be discontinued and appropriate measures such as administration of potassium preparations should be take.
2) Myopaty: Myopathy may occur as a result of hypokalemia. The patient should be carefully monitored, and if any abnormality such as weakness, convulsion/paralysis of limbs, etc. are observed, administration should be discontinued and appropriate measures such as administration of potassium preparations should be taken.
3) hepatic dysfunction and jaundice: Hepatic dysfunction and/or jaundice with elevation of AST (GOT), ALT (GPT), AL-P and γ‐GTP or other symptoms may occur. The patient should be carefully monitored for abnormal findings. Administration should be discontinued and appropriate therapeutic measures should be taken, if abnormalities are observed.
(2) Other adverse reactions
Hypersensitivity : Rush, Urticaria, etc.
Gastrointestinal: Anorexia, Epigastric distress, Soft feces, Diarrhea, etc.